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Cell-surface protein disulfide isomerase (PDI) has been proposed to promote disulfide bond rearrangements in HIV-1 envelope protein (Env)
that accompany Env-mediated fusion. We evaluated the role of PDI in ways that have not been previously tested by downregulating PDI with
siRNA and by overexpressing wild-type or variant forms of PDI in transiently and stably transfected cells. These manipulations, as well as
treatment with anti-PDI antibodies, had only small effects on infection or cell fusion mediated by NL4-3 or AD8 strains of HIV-1. However, the
cell-surface thiol-reactive reagent 5, 5′-dithiobis(2-nitrobenzoic acid) (DTNB) had a much stronger inhibitory effect in our system, suggesting that
cell-surface thiol-containing molecules other than PDI, acting alone or in concert, have a greater effect than PDI on HIV-1 Env-mediated fusion.
We evaluated one such candidate, thioredoxin, a PDI family member reported to reduce a labile disulfide bond in CD4. We found that the ability of
thioredoxin to reduce the disulfide bond in CD4 is enhanced in the presence of HIV-1 Env gp120 and that thioredoxin also reduces disulfide bonds
in gp120 directly in the absence of CD4. We discuss the implications of these observations for identification of molecules involved in disulfide
rearrangements in Env during fusion.
Published by Elsevier Inc.Keywords: HIV-1; Fusion; Protein disulfide isomerase; Thioredoxin; siRNAIntroduction
HIV-1 entry into host cells is mediated by its envelope
glycoprotein (Env), a type I membrane protein present on the
virion in the form of a trimer. Each mature monomer is
composed of a surface (SU) protein gp120 and a transmembrane
(TM) protein gp41, held together through non-covalent interac-
tions. In a generally accepted model for HIV-1 entry, extensive
conformational changes in Env occur following binding of SU to
receptor CD4 and co-receptor (e.g., CCR5 or CXCR4) (Gallo et
al., 2003; Greenberg et al., 2004; Moore and Doms, 2003).
These conformational changes may be associated with reduction
of one or more of the 9 disulfide bonds in gp120. Protein
disulfide isomerase (PDI) has been suggested to catalyze the
disulfide reduction and hence provide a potential target for anti-
HIV therapy (Barbouche et al., 2003; Barbouche et al., 2005;⁎ Corresponding author. Fax: +1 301 402 0226.
E-mail addresses: wou@niaid.nih.gov (W. Ou), jsilver@nih.gov (J. Silver).
0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2006.01.041Fenouillet et al., 2001; Gallina et al., 2002; Markovic et al.,
2004; Ryser et al., 1994; Ryser and Fluckiger, 2005).
PDI is a member of a family of structurally related
chaperones, some of which contain CXXC motifs (“vicinal”
cysteines) that catalyze the formation, reduction, and rearrange-
ment of disulfide bonds of proteins, primarily in the
endoplasmic reticulum (ER) (Noiva, 1999; Wang, 1998;
Wilkinson and Gilbert, 2004). PDI can also be secreted and
bind to the cell surface, but, without a classical membrane
attachment site, much less PDI is present on the cell surface than
in the ER. Cell-surface PDI has been postulated to be involved
in numerous processes including cell adhesion, nitric oxide
signaling, modulation of thrombospondin activity, shedding of
the human thyrotropin receptor ectodomain, reduction of a
disulfide bridge in diphtheria toxin required for cell entry, and
maintenance of the reductive status of the plasma membrane
(Turano et al., 2002).
The conclusion that cell-surface PDI is involved in HIV-1
Env-mediated membrane fusion is based on observations that
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and HIV-1 Env-mediated cell fusion (Barbouche et al., 2003;
Fenouillet et al., 2001; Gallina et al., 2002; Markovic et al.,
2004; Ryser et al., 1994). Such inhibitors include DTNB, a
membrane-impermeant reagent that reacts non-specifically with
free thiols; bacitracin, a mixture of bacterial peptides with PDI-
inhibiting and non-specific effects (Mou et al., 1998; O'Neill et
al., 2000); arsenical compounds that react with vicinal
cysteines, which are present in many PDI family members as
well as other proteins; and anti-PDI antibodies. A concern with
these experiments is that they do not uniquely identify PDI as
the relevant thiol-containing molecule. Even anti-PDI anti-
bodies can have non-specific effects; for example, their
inhibition of platelet aggregation and secretion was recently
shown to be due to the Fc moiety rather than the antigen
combining site (Essex and Li, 1999). Additional circumstantial
evidence implicating PDI was provided by observations that
purified PDI can reduce disulfide bonds in soluble gp120 and
PDI co-localized with CD4 and HIV-1 co-receptors in some
cells (Gallina et al., 2002; Markovic et al., 2004), putting it in
the right place to promote disulfide rearrangements in gp120.
However, other cell-surface molecules share these properties.
For example, CD4, which directly binds gp120, has a labile,
arsenical-reactive disulfide bond in its ectodomain (Matthias et
al., 2002), raising the possibility that a reduced form of CD4
might itself be the proximate reducing agent for disulfides in
gp120.
Further indirect evidence supporting a role for a protein with
vicinal thiols in HIV-1 Env-mediated fusion comes from
provocative observations that SU envelope proteins from
several related retroviruses encode CXXC motifs. In the case
of murine leukemia virus (MLV), this motif is used during Env-
mediated fusion to isomerize a disulfide linking SU and TM
(Wallin et al., 2004; Wallin et al., 2005). Thus, some
retroviruses may have picked up a motif for rearranging Env
disulfides that HIV-1 relies on the cell to provide.
Given that much of the data implicating PDI in HIV-1 Env-
mediated fusion are indirect or do not rule out a contribution by
related molecules, we wished to evaluate its role in new ways.
Here, we describe studies in which we evaluated the effect of
downregulating PDI via siRNA or overexpressing wild-type
(wt), cell-surface-targeted, or enzymatically defective forms of
PDI. These manipulations had only small effects on HIV-1 Env-
mediated fusion. In a parallel assay, however, HIV-1 Env-
mediated cell fusion was markedly inhibited by DTNB. This
suggested that other cell-surface thiol-containing molecules,
alone or in concert, might be more important than PDI in HIV-1-
Env-mediated fusion. We evaluated one candidate, thioredoxin,
a cell-surface PDI family member reported to reduce a disulfide
bond in CD4. We confirmed that exogenous thioredoxin
reduces a disulfide bond in CD4 and found that this activity
was enhanced in the presence of gp120. Furthermore,
thioredoxin reduced disulfide bonds in HIV-1 Env in the
absence of CD4. Taken together, our results suggest that other
molecules besides PDI can promote the disulfide bond
rearrangements associated with HIV-1-mediated membrane
fusion.Results
Knockdown of the endogenous PDI by siRNA
One way to see whether PDI contributes to HIV-1 fusion is to
“knock down” the endogenous protein using siRNA. We
selected four target sequences in PDI using an online tool
provided by Whitehead Institute for Biomedical Research
(http://jura.wi.mit.edu/siRNAext/) and made siRNA expression
constructs based on pSilencer2.1-U6hygo (Ambion). A non-
specific control siRNA (Ambion) in the same vector was used
as a negative control (Fig. 1A). Three of the four siRNA
constructs decreased expression of endogenous PDI, as judged
by immunofluorescence, in transient transfections of U373 cells
(Vodicka et al., 1997) in which co-transfected pEGFP was used
to identify transfected cells (Fig. 1B).
To see if this downregulation of PDI would decrease
susceptibility to HIV-1 infection, we selected stable clones of
siRNA-transfected indicator cells. For these experiments, we
used an HeLa-derived, HIV fusion indicator line TZM-bl cells
(Derdeyn et al., 2000; Wei et al., 2002) because the U373 cells
used in transient expression studies contained multiple selective
markers that would complicate efforts to generate stable cell
lines. TZM-bl cells express the CD4 receptor, CXCR4, and
CCR5 co-receptors and contain quiescent luciferase and beta
galactosidase (lacZ) reporter genes under the control of HIV-1
LTRs. Infection by HIV leads to expression of Tat, which
induces luciferase and lacZ. Two PDI knockdown cell clones
(1-2 and 4-1) and one control siRNA clone (5–1) were used in
the following experiments. Western blot of total cell lysate (Fig.
2A) and surface biotinylated proteins (Fig. 2B) showed that
steady state PDI levels were reduced ∼70–90% in the
knockdown clones. Immunofluorescence of permeabilized
cells using anti-PDI antibody was consistent with the Western
blot data (Fig. 2C).
To see if decreased PDI protein levels correlated with
susceptibility to virus infection, equal numbers of cells were
infected with T-tropic (NL4-3) or M-tropic (AD8) HIV-1 virus
or no virus as control. LacZ activity was assayed 48–60 h after
infection. LacZ activity increased about 50-fold as a result of
infection. A representative experiment of three performed is
shown (Fig. 2D). Variability in lacZ activity among triplicate
cultures of a given cell line was ∼25% in a single experiment
(see standard deviation error bars in Fig. 2D). In three
independent experiments, the infectibility of the knockdown
clones as measured by mean lacZ activity of triplicate cultures
varied from 30 to 130% that of parental TZM-bl cells infected
with AD8 virus and 60–130% that of parental TZM-bl cells
infected with NL4-3 virus. Since this range includes 100%,
downregulating PDI did not significantly reduce susceptibility
in our system. The range of values we obtained in repeat
experiments indicates that differences smaller than about a
factor of two are not significant in our experiments.
To evaluate the possibility that the clones differed in
sensitivity to Tat induction of lacZ, we infected equal numbers
of cells from each clone with a Tat-expressing HIV vector
pseudotyped by VSV-G Env protein. LacZ activity 2 days later
Fig. 1. Transient knockdown of endogenous PDI in U373 cells. (A) Sequences of siRNA targeting PDI (#1–4) and non-specific control siRNA (#5). (B) U373 cells
were transiently co-transfected with gene silencing vectors encoding PDI siRNA or control siRNA and pEGFP, which was used to identify transfected cells. Forty-
eight hours later, the cells were fixed, permeabilized, and stained with mouse anti-PDI monoclonal antibody plus Cy5-anti-mouse IgG (red). Column labels indicate
genes detected; row labels indicate siRNA vectors transfected. White arrows point to transfected cells with reduced level of PDI.
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clone 4-1, clone 1-2, and the control siRNA clone 5-1 was
102%, 102%, and 65% that in parental TZM-bl cells. These
differences are within experimental error and indicate that the
PDI-downregulated clones did not differ from parental cells in
sensitivity to lacZ induction by Tat. To be sure that the clones
did not differ in infectibility by VSV-G pseudotypes, we
infected equal numbers of cells with a murine leukemia virus
vector encoding lacZ pseudotyped by VSV-G. LacZ activity 2
days later was about 100 times that in uninfected cells. LacZ
induction in clone 4-1, clone 1-2, and the control clone 5-1 was
112%, 92%, and 85% that in parental TZM-bl cells. Since these
differences are not significant, we conclude that the clones are
equally infectible by VSV-G pseudotypes.
Compared to parental cells, clone 4-1 was resistant to
syncytium formation when co-cultured with cells expressing
NL4-3 Env (Fig. 3, left panels), but not when co-cultured with
cells expressing the AD8 Env (Fig. 3, right panels). This may
be related to the fact that AD8 Env is expressed at higher levels
than NL4-3 Env as judged by Western blot analysis (data not
shown). The resistance of clone 4-1 to syncytium formation by
NL4-3 Env as detected by light microscopy was associated with
only a 50% reduction in fusion measured by luciferase assay:
aliquots of the cells shown in Fig. 3 were assayed for luciferase
activity and compared to cells co-cultured with 293HEK cellsnot expressing Env and Tat as a negative control. Luciferase
activity increased 30 ± 4-fold (mean ± standard deviation for
triplicate samples) when clone 4-1 cells were co-cultivated with
293HEK cells expressing NL4-3 Env and Tat versus 57 ± 1-fold
for parental TZM cells in the same assay. The corresponding
luciferase induction numbers were 585 ± 17 versus 521 ± 10 on
co-culture with 293HEK cells expressing AD8 Env. Greater
induction of luciferase by AD8 Env compared to NL4-3 Env is
consistent with AD8 Env being expressed at a higher level.
Discrepancy between luciferase induction and syncytium
formation detected by light microscopy has been noted
before and may result from “kiss and run” fusion or
luciferase being induced in syncytia too small to be easily
detected by light microscopy (Ou et al., 2004). We conclude
that syncytium formation detected by light microscopy can
provide a more sensitive assay in some circumstances for
factors that affect fusion as it appears to exhibit a more “all
or none” response.
Effect of anti-PDI antibody
First, we confirmed that PDI is present on the surface of
TZM indicator cells using flow cytometry. Fig. 4A shows the
results of staining live TZM cells using an anti-PDI monoclonal
antibody (clone RL77, Affinity Bioreagents); the mean
Fig. 2. Effect of knockdown of the endogenous PDI by siRNA. (A) Western blot
analysis of cell lysate using anti-PDI antibody (upper panel) in TZM cells and
TZM clones containing control siRNA (5-1) or PDI siRNA (1-2 and 4-1). The
first part of the clone name indicates the siRNA used (Fig. 1A). Anti-actin
(bottom panel) was used as a loading control. (B) Surface PDI was detected by
biotinylating surface proteins, purifying biotinylated proteins with avidin
agarose, and analyzing the avidin agarose eluate by Western blot with anti-PDI
antibody (upper panels) or anti-integrin antibody (lower panels) as a loading
control. (C) Immunofluorescence staining of parental TZM cells and one of the
stable knockdown clones (4-1) using anti-PDI antibody after fixation and
permeabilization. (D) Relative susceptibility of parental TZM cells, control
siRNA, and PDI knockdown clones to infection with HIV-1. These cells contain
a LacZ reporter activated by HIV-1 Tat. Equal numbers of cells were infected
with X4 (NL4-3, gray bars) or R5 (AD8, empty bars) viruses. Sixty hours later,
cells were lysed for LacZ assay. LacZ activity is normalized to that of TZM cells
infected with the same virus. Mean values ± standard deviations from one
experiment done in triplicate are shown.
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with an isotype-specific control antibody. Similar results were
obtained with two other monoclonal antibodies to PDI (Clone
RL90 of Affinity Bioreagents and SPA-891 of Stressgen,
Victoria, BC, Canada). Staining lymphoid cells (CEM.NKR.
CCR5.Luc; Spenlehauer et al., 2001; Trkola et al., 1999) with
these antibodies gave similar results, indicating that TZM cells
contain about the same amount of surface PDI. When HeLa-
TZM cells were co-cultivated with HEK293 cells expressing
NL4-3 Env, SPA-891 anti-PDI antibody inhibited syncytium
formation (Fig. 4B). However, this anti-PDI antibody did not
inhibit AD8 Env-mediated syncytium formation.
Although anti-PDI antibody inhibited NL4-3 Env-induced
syncytia, it had little effect on luciferase induction in cell fusion
or virus infection. In the cell fusion assay, TZM-bl cells were
co-cultivated with 293HEK cells transiently transfected the day
before with an expression vector for HIV Env and Tat, andluciferase activity was measured 6–24 h after co-culture.
Luciferase activity increased more than 50-fold as a result of
cell fusion. Mean luciferase activity in cells incubated with
75 μg/ml of SPA-891 anti-PDI antibody was ∼80% that of cells
incubated with no antibody or a control anti-actin antibody (Fig.
4C). The two Affinity Bioreagents monoclonal anti-PDI
antibodies at 80 μg/ml also had little effect on luciferase
induction: luciferase activity was ∼80% that of the no antibody
control in TZM-bl cells and 30–40% that of the control in CEM
cells bearing an LTR-driven luciferase reporter. In the virus
infection assay, TZM-bl cells were pretreated with R77 anti-PDI
antibody or control antibody for 60 min and then infected with
NL4-3 or AD8 viruses. PDI antibody was left in the culture, and
lacZ activity was measured 2 days later. Infection with X4 or R5
viruses led to a ∼100-fold induction of lacZ activity. After
infection with X4 (R5) virus, lacZ induction in cells treated with
anti-PDI antibody was 1.5 (0.6) times that of cells treated with
control antibody. We interpret these differences as within
experimental variability in our system.
Overexpression of wild-type or mutant PDI has little effect on
HIV-1 Env-mediated cell fusion
As an alternative to decreasing PDI with siRNA and
blocking PDI with anti-PDI antibodies, we investigated the
effect of overexpressing wild-type PDI, PDI targeted to the
plasma membrane, or variants of PDI with mutations in the
cysteines that mediate disulfide exchange. Our reasoning was
that, if PDI were limiting for HIV-1 fusion, overexpressing it on
the cell surface should increase fusion. Alternatively, since only
a small fraction of PDI gets to the cell surface (see below),
overexpressing enzymatically inactive forms might compete for
transport or CD4 association and decrease the amount of
functional PDI on the cell surface (Gallina et al., 2002;
Markovic et al., 2004).
To overexpress PDI in mammalian cells, we transferred
the wild-type PDI coding sequence to the pCI expression
vector to make pPDI. To compare PDI expression in
transfected versus non-transfected cells, we co-transfected
pPDI with an expression vector for a membrane form of
enhanced yellow fluorescent protein (pEYFP-Mem) as a
marker for transfected cells and visualized PDI by staining
with monoclonal anti-PDI antibody followed by a Cy5-
labeled secondary antibody. Results for CHO cells are shown
in Fig. 5A. Similar results were obtained with U373 cells.
Endogenous PDI was easily detected in permeabilized cells
(P, lower panels) but not in non-permeabilized cells (NP,
upper panels), consistent with most PDI being in the ER.
Increased intracellular PDI staining was seen in permeabilized
cells expressing EYFP, consistent with overexpression of the
transfected PDI gene. The overexpressed PDI was mainly
internal, rather than on the cell surface, indicated by the lack
of red signal in non-permeabilized cells (top middle panel)
and the green signal from cell-surface EYFP-mem forming a
“rim” around the red PDI signal (lower right panel). This
result is expected as wild-type PDI carries a C-terminal
KDEL ER retention signal.
Fig. 3. Resistance of knockdown clone 4-1 to syncytium formation by NL4-3 Env. TZM cells (lower panels) or clone 4-1 cells (upper panels) were co-cultivated with
HEK293 cells transiently transfected to express NL4-3 Env (left panels) or AD8 Env (right panels). Pictures were taken using a conventional microscope 6 h after co-
culture. Arrows indicate syncytia.
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deleted the KDEL ER retention signal and substituted a
carboxy-terminal, glycosylphosphatidylinositol (GPI) attach-
ment sequence (plasmid pPDIgpi). Transfection of this
vector led to overexpression of PDI on the cell surface,
indicated by surface staining with anti-PDI antibody in non-
permeabilized cells (Fig. 5B). Cells transfected with this
vector also overexpressed PDI internally, indicated by the
stronger red cytoplasmic signal in cells co-transfected with
an expression vector for cytosolic enhanced green fluores-
cent protein (EGFP) as a marker for transfected cells (Fig.
5C, first row). To confirm the specificity of the anti-PDI
antibody, in some vectors, an HA expression tag was added
to the N-terminus of PDI. Anti-HA staining showed the
same pattern as anti-PDI staining (not shown). We conclude
that the pPDIgpi expression vector led to the expected
overexpression of PDI on the cell surface, as well as
intracellularly.
PDI has two CGHC motifs that are active sites for the
isomerase function (Fig. 5D). Mutation of cysteine to serine
causes the loss of PDI isomerase activity (Hawkins and
Freedman, 1991; Vuori et al., 1992a, 1992b). We mutated
cysteine to serine in both motifs to make pPDI-CS2 and
pPDIgpi-CS2. Anti-PDI antibody staining showed that
pPDIgpi-CS2 was overexpressed intracellularly and on the
cell surface, indistinguishably from pPDIgpi (Fig. 5C, middle
row). Similar staining results were obtained for overexpressed
forms of PDI in U373 cells (data not shown).
To investigate the effect of overexpressing wild-type or
mutant forms of PDI on HIV-1 Env-mediated cell fusion, weused a transient transfection assay that restricted read-out
predominantly to cells that were transfected with the PDI
expression constructs. This was accomplished by co-transfect-
ing target cells with the PDI expression vector plus a luciferase
reporter gene under the control of the transcriptional transacti-
vator tTA. These cells were then mixed with HEK293 cells
transiently transfected to express HIV-1 Env plus tTA; cell
fusion allowed tTA to activate luciferase (Fig. 6A) (Ou et al.,
2004). Induction of luciferase activity in this system was co-
receptor-specific and led to 10- to 100-fold increases in
luciferase (see below). For target cells, we chose U373 cells
because they transfect well, showed increased/decreased levels
of PDI after transfection with overexpression/siRNA vectors,
and constitutively express CD4, CXCR4, and CCR5. We did
not use TZM-bl indicator cells in this assay because they
contain an LTR-driven Luc reporter that would be activated by
cell fusion in cells that did not take up the PDI expression
vector.
Using this cell fusion assay system, overexpression of cell-
surface-targeted wild-type PDI did not promote fusion, and
overexpression of the cell-surface-targeted cys-to-ser mutant
PDI did not inhibit fusion, either for an X4 tropic or an R5 tropic
HIV-1 Env (Figs. 6B and C). Similar results were obtained for
the non-gpi-tailed versions of wild-type and mutant PDI (data
not shown). We also tested the PDI siRNA expression vectors
that downregulated endogenous PDI (Fig. 1B); again, no
inhibition was detected (Fig. 6D). In summary, in cell fusion
assays using U373 cells, HeLa-TZM cells, or CEM cells,
overexpression of PDI showed little effect on luciferase
induction.
Fig. 4. Effect of anti-PDI antibody on cell fusion measured by syncytia formation and luciferase induction. (A) Flow cytometry of TZM cells stained with anti-PDI
antibody (clone RL77) versus isotype control antibody. (B) Inhibition of syncytium formation. TZM cells were pre-incubated with anti-PDI antibody or no antibody
for 30 min then HEK293 cells expressing NL4-3 Env were added. Antibody was left in the medium. Pictures were taken using a conventional microscope 16 h later.
Arrows indicate syncytia in control cells; syncytia were not seen cells incubated with anti-PDI antibody. (C) Lack of effect on luciferase induction. Co-cultivated cells
from panel B were lysed, and luciferase activity was assayed. The relative luciferase activity was calculated by dividing the relative light units of the indicated cells by
that of TZM cells co-cultured with non-transfected HEK293 cells (background). Mean values ± standard deviations from one experiment done in triplicate are shown.
Similar results were obtained in an independent experiment.
411W. Ou, J. Silver / Virology 350 (2006) 406–417DTNB inhibits HIV-1 Env-mediated cell fusion
To see if our cell fusion assay (Fig. 6A) was insensitive to
thiol-protein modification in general, we treated indicator cells
with the non-specific thiol-reactive reagent DTNB just before
co-culture with cells expressing HIV-1 Env and tTA. For R5-
tropic envelope (AD8) and U373-CCR5 indicator cells, 2 mM
DTNB inhibited the fusion-induced firefly luciferase activity
97%; for X4-tropic envelope (NL4-3) and U373-CXCR4
indicator cells, fusion-induced firefly luciferase was inhibited
85%. To evaluate possible DTNB toxicity, in this experiment,
the indicator cells were transfected with a renilla luciferase
plasmid (pRL-TK), the expression of which is independent of
cell fusion, along with the tTA-dependent firefly luciferase
plasmid pTRE-Luc. The control renilla luciferase was inhibited
only 20% (Figs. 7A and B), indicating that the decrease in firefly
luciferase activity was mainly due to inhibition of cell fusion
rather than cell toxicity. DTNB inhibited fusion to a similar
extent in a cell fusion assay using HeLa TZM-bl indicator cells
(data not shown). These results show that DTNB inhibited HIV-
1 Env-mediated cell–cell fusion to a much greater extent than
did alterations in PDI expression. One possible interpretation of
this result is that DTNB inhibition is mediated by its action on
molecules other than, or in addition to, PDI.Thioredoxin reduces disulfide bonds in HIV-1 gp120
While DTNB could be acting through any one, or
combination of, cell-surface thiol-containing proteins, we
investigated one interesting candidate, thioredoxin, a PDI
family member on the surface of many cells that has been
shown to reduce a labile disulfide bond in the ectodomain of
CD4 (Matthias et al., 2002). This observation raised the
possibility that the reduced disulfide in CD4 might be the
proximate reducing agent for disulfide bonds in gp120. To
investigate this possibility, we mixed purified thioredoxin with
soluble, 2-domain CD4 (sCD4), gp120, or sCD4 plus gp120. To
detect reduced disulfides, we used a biotinylation reagent (3-(N-
maleimido-propionyl) biocytin (MPB)) that reacts with free
thiols. Following polyacrylamide gel electrophoresis, biotiny-
lated proteins were detected on Western blot with avidin
peroxidase. The results (Fig. 8) show that the thioredoxin we
used (human, MW 14 kDa) had free thiols and migrated as
monomer, dimer, and trimer species (lane 3). In the absence of
thioredoxin, there were no (or very few) free thiols in 2-domain
sCD4 (MW 24 kDa) (lane 1) or gp120 (lane 4). Thioredoxin
reduced one or more disulfide bonds in sCD4 (lane 2) and also
in HIV-1 gp120 (lane 5). When thioredoxin, sCD4, and gp120
were combined, sCD4 was more efficiently reduced (lane 2 vs.
Fig. 5. Immunofluorescence analysis of cells transfected with wild-type or mutant PDI expression vectors. In panels A–C, column labels designate the proteins whose
fluorescence images are shown. The left row labels indicate if the cells were permeabilized (P) or not permeabilized (NP), and the right row labels indicate the PDI
genes transfected. (A) CHO cells were transiently co-transfected with pPDI and pEYFP-Mem, which is used to identify transfected cells. Forty-eight hours later, the
cells were fixed, permeabilized or not, and stained with mouse anti-PDI monoclonal antibody plus Cy5-anti-mouse IgG (red). (B) CHO cells were transfected with
pPDIgpi and stained with anti-PDI antibody in the same way as in panel A. (C) U373 cells were co-transfected with pEGFP and pPDIgpi (top panels), pPDIgpi-CS2
(middle panels), or empty vector (bottom panels), fixed, permeabilized, and stained with anti-PDI antibody as in panel A. (D) Diagrams of wild-type and mutant PDI
constructs used. a, b, b′, a′, and c are functional domains of PDI. CGHC and SGHS designate wild-type and mutant amino acids in the PDI active motif.
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increased the reduction of disulfide bonds in gp120 (lane 5 vs.
6). The ∼70 kDa species labeled “*” (lanes 5 and 6) may be a
product of proteolytic cleavage in the V3 loop (Werner and
Levy, 1993) or contaminant in the gp120 preparation.
Discussion
We evaluated the role of PDI in HIV-1 Env-mediated
membrane fusion by altering PDI levels or function with
siRNA, anti-PDI antibodies, and overexpression of wild-type
and mutant forms of PDI. We found that downregulating PDI
with siRNA or anti-PDI antibodies reduced syncytium
formation in some experiments with NL4-3 Env, but not AD8
Env. These data are consistent with prior reports that PDI
inhibitors block syncytium formation (Fenouillet et al., 2001).
However, downregulation of PDI by siRNA or antibodies had
only small or inconsistent effects on virus infection or cell
fusion measured by induction of lacZ or luciferase reporters in
our experiments. This contrasts with published reports that anti-PDI antibodies inhibit HIV-1 infection (Markovic et al., 2004).
The discrepancy with our results could be due to the use of more
sensitive assays by other groups. For example, in our cell fusion
assay, we co-cultured Env and indicator cells for 6–16 h to
allow maximal expression of the reporter gene, whereas a dye
transfer assay to detect cell fusion in another report was
performed after 1 h of co-culture. Blocking PDI with antibody
may delay fusion but not prevent it after a longer incubation.
Assays that amplify the effect of small changes in susceptibility
may give a misleading impression of the relative strength of an
inhibitory interaction. For comparison, neutralizing antibodies
and C-helix peptides reduce fusion ∼100-fold in our cell fusion
assays. From a practical point of view, the fact that fusion was
inhibited only slightly by antibodies in our experiments leads us
to conclude that PDI does not play a crucial role in HIV Env-
mediated fusion.
The small magnitude of the effects we observed after siRNA
downregulation of PDI could be due to achieving only a partial
decrease in PDI levels. If true, this would imply that only small
amounts of PDI are required for HIV-1 fusion, which in theory
Fig. 8. Thioredoxin reduces disulfide bonds in HIV-1 gp120 as well as CD4.
HIV-1 gp120, 2-domain CD4, and thioredoxin (Trx) were incubated alone or in
different combinations as indicated then biotinylated on free thiols with MPB.
Streptavidin peroxidase was used in Western blot to detect the biotinylation.
Fig. 6. Alterations in PDI expression have little effect on HIV-1 Env-mediated cell fusion. (A) Cell fusion assay to test the effect of transfected PDI or siRNA. U373
cells were transfected with the test plasmid (wt or mutant PDI, or siRNA vector) plus a luciferase reporter gene pTRE-Luc, which is under the control of the
transcriptional transactivator (tTA). HEK293 cells were transiently transfected to express HIV-1 Env plus tTA. Twenty-four (wt or mutant PDI vector) or 48 (siRNA
vector) h later, the transfected cells were co-cultivated. Cell fusion allowed tTA to activate the luciferase reporter. (B) U373-MAGI-CXCR4CEM cells (U373 X4) co-
transfected with pTRE-Luc and surface-targeted wild-type PDI (first bar), mutant PDI (second bar), or empty vector (third and forth bars) were co-cultivated with tTA
plus HIV-1 NL4-3 envelope transfected HEK293 cells (first three bars) or plain HEK293 (forth bar, “bkgd”). Luciferase activity was assayed 16 h after co-cultivation.
Mean values ± standard deviations of relative light units (RLU) from one experiment done in triplicate are shown. Similar results were obtained in several independent
experiments. (C) Same as panel B except that the indicator cell is U373-MAGI-CCR5E (U373 R5) and the HIV-1 envelope is from strain AD8. (D) Same as panel B
except that U373 X4 cells were co-transfected with pTRE-Luc plus PDI siRNA vector (first three bars) or control siRNA (forth bar).
Fig. 7. DTNB markedly inhibits HIV-1 Env-mediated cell fusion. (A) U373-
CCR5 cells co-transfected with pTRE-Luc plus pRL-TK were co-cultivated
with HEK293 cells expressing HIV-1 AD8 Env and tTA, in the absence (control)
or presence of 2 mM DTNB. Sixteen hours later, firefly and renilla luciferase
activities were assayed. The relative light units of the controls (no DTNB) was
designated as 100. Mean values ± standard deviations from one experiment done
in triplicate are shown. Similar results were obtained in an independent
experiment. (B) Same as panel A except that the indicator cells were U373
CXCR4 and the HIV-1 Env was from strain NL4-3.
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prevent HIV-1 entry. However, we think that the degree of PDI
downregulation we achieved provides a reasonable test of the
role of PDI since it was sufficient to efficiently inhibit infection
by polyoma virus, which uncoats in the ER where PDI is
abundant (J. Gilbert, T. Benjamin, W. Ou, J. Silver, unpublished
results).
Our failure to detect promotion of cell fusion by over-
expressing cell-surface PDI implies that fusion is not limited by
PDI in this cell fusion assay. We cannot rule out the possibility
that the gpi tail might target PDI to membrane domains (“rafts”)
(Simons and Vaz, 2004) where PDI might be inactive (Liao et
al., 2003; Lu et al., 2002; Rawat et al., 2003; Kozak et al., 2002;
Popik and Alce, 2004).
The fact that DTNB inhibited fusion in our cell fusion system
more robustly than anti-PDI antibody or alterations in
expression of PDI could be due to more efficient elimination
of surface PDI activity by DTNB than by antibody or siRNA.
We think this is unlikely in the case of antibody since we used
concentrations ∼500 nM, which should bind almost all PDI
molecules. A simpler explanation that we favor is that other
cell-surface thiol-containing molecules that are targeted by
DTNB can substitute for PDI in promoting HIV Env-mediated
fusion.
The fact that PDI can reduce disulfide bonds in gp120 in
vitro has been used to bolster the argument that it has a role in
HIV-1 Env-mediated fusion. Our observation that thioreductase
also reduces disulfide bonds in gp120 is novel (Matthias et al.,
2002) and shows that this activity is shared by other PDI family
members. Since much of the evidence implicating PDI is based
on drugs that react with vicinal thiols, which are present in PDI
family members as well as some other proteins, our observation
raises the possibility that the real target of these inhibitors may
not have been identified. We confirmed that thioreductase can
reduce a disulfide in sCD4 (Matthias et al., 2002) and found that
sCD4 was more efficiently reduced by thioredoxin in the
presence of gp120. This suggests that stress in the CD4 disulfide
bond may be increased when CD4 binds gp120. Better
understanding of how protein interactions, such as gp120
binding to CD4, affects the sensitivity of intra-molecular
disulfide bonds to reduction is potentially very important for
further insights into disulfide rearrangements that occur during
virus-mediated fusion. We caution, however, that the relevance
of in vitro disulfide bond reduction assays to in vivo phenomena
remains speculative.
Materials and methods
Constructs
To make pPDIgpi (Fig. 5D), the PDI coding sequence
excluding the signal peptide and KDEL sequence was amplified
from pVLβ (Vuori et al., 1992a, 1992b) using primers: 5′
GCACCGGTCTACCCATACGATGTTCCAGATTACGCTGAC-
GCCCCCGAGGAGGAGGACC 3′ and 5′ ACTTGTACAG-
CACAGCTTTCTGATCATCGTCTTC 3′. The sequence in
italics is an HA expression tag. The PCR product was cut atAgeI and BsrGI sites (underlined) introduced for cloning and
ligated into pEYFP-GL-GPI (Keller et al., 2001) cut with the
same enzymes, replacing YFP. PDIgpi-CS2 was made by site-
directed mutagenesis using the following primer pairs to mutate
the first and second CGHC motif, respectively: CCTGCTGG-
TGGAATTCTATGCCCCTTGGTCTGGCCACTCCAAGG-
CTCTGGCCCC 3′ and 5′ GGGGCCAGAGCCTTGGAGT-
GGCCAGACCAAGGGGCATAGAATTCCACCAGCAGG
3′, and 5′ CGTCTTTGTGGAATTCTATGCCCCATGGTCT-
GGTCACTCCAAACAGTTGGCTCC and 5′ GGAGCCAAC-
TGTTTGGAGTGACCAGACCATGGGGCATAGAATTC-
CAC AAAGACG 3′. One silent mutation (in bold) was
introduced to create an EcoRI restriction site (underlined) for
clone identification. pPDI was made by ligating the PDI
coding sequence, cut from pVLβ (Vuori et al., 1992a, 1992b)
with XmaI and EcoRI, into pCI (Promega, Madison, WI) cut
with the same enzymes. pPDI-CS2 was generated by PCR,
amplifying PDIgpi-CS2 with primers: 5′ CCTGGTGCGCGC-
CGACGCCCCCGAGGAGGAGG 3′ and 5′ CAGCTTTCT-
GATCATCGTCTTCCTC 3′, cutting with BssHII (underlined)
and BclI (in the middle of PDI gene) and ligating into pPDI
cut with the same enzymes. Vectors expressing PDI siRNA
(1–4) were based on pSilencer2.1-U6hygo (Ambion, Austin,
TX), into which annealed oligos (designed according to the
Vector's Instruction Manual) encoding different PDI target
sequences (Fig. 1A) were ligated between HindIII and BamHI
sites. An annealed oligo with non-specific sequence was
ligated in the same way to generate the control vector. pdl1443
is an expression vector for T-tropic HIV-1 (NL4-3) Env and
Tat, made by partially deleting gag and pol sequences from
pNL4-3 (Felser et al., 1989); pAD8env is the same as pdl1443
with M-tropic HIV-1 (AD8) Env substituted for NL4-3 Env.
pEGFP, pEYFP-Mem, pTet-Off, and pTRE-Luc were bought
from Clontech (Palo Alto, CA), pCL-MFG-LacZ from
Imgenex (San Diego, CA), and pRL-TK from Promega
(Madison, WI).
Cell lines
TZM-bl (Derdeyn et al., 2000; Wei et al., 2002), U373-
MAGI-CXCR4CEM, U373-MAGI-CCR5E (Vodicka et al.,
1997), CHO, and HEK293 were maintained in Dulbecco's
modified Eagle's medium (GIBCO-BRL, Grand Island, NY)
supplemented with 10% fetal calf serum, 2 mM glutamine,
100 U penicillin, and 100 U streptomycin. CEM.NKR.CCR5.
Luc (Spenlehauer et al., 2001; Trkola et al., 1999) was grown in
RPMI-1640 (GIBCO-BRL) supplemented with 10% fetal calf
serum, 2 mM glutamine, 100 U penicillin and 100 U
streptomycin. All cell lines were kept at 37 °C in a 5% CO2
humidified incubator.
Transfection and selection
Cells were seeded 1 day before and transfected when they
were around 70–90% confluent. For six-well plates, 3–5 μg total
of plasmid(s) and 6–10 μl Lipofectatime 2000 (Invitrogen,
Carlsbad, CA) per well were diluted in 250 μl Opti-Mem
415W. Ou, J. Silver / Virology 350 (2006) 406–417medium (Invitrogen) and mixed well. The complex was allowed
to form at room temperature for 20–30 min and then added to
cells in 2 ml antibiotic-free fresh medium. The stable cell lines
were selected 24 h after transfection by subcultivating at a 1:10
dilution in medium containing 0.4 mg/ml hygromycin B
(Invitrogen). Following 2 weeks of selection, cell clones were
picked and maintained in complete medium plus 0.1 mg/ml
hygromycin B.
Western blot analysis
Proteins were resolved on SDS-PAGE precast gel and
transferred onto a PVDF membrane. The membrane was
blocked for 1 h at room temperature in blocking buffer (5%
nonfat milk in TBST buffer (25 mM Tris–HCl [pH 8.0],
150 mM NaCl, 0.1% Tween 20) and incubated with primary
antibodies in blotting buffer for 1 h (1% nonfat milk in TBST
buffer) at room temperature. Following washing 4 × 10 min
using TBST buffer, the blots were incubated with secondary
antibodies for 1 h at room temperature and washed 4 × 10 min
again. Specific proteins were visualized with the enhanced
chemiluminescence detection system (Pierce). The primary
antibodies used were mouse anti-HA and anti-β-actin, 1:5000
dilution (Sigma, St. Louis, MO); mouse anti-PDI clone RL77,
1:2500 dilution (Affinity Bioreagents, Golden, CO); the
secondary antibodies were horseradish-peroxidase-conjugated
anti-mouse immunoglobulin G (Pierce, Rockford, IL) (1:5000).
Immunostaining
One day before staining, transfected cells were seeded in 8-
well coverglass chambers at a density of 50%. The cells were
fixed with 4% paraformaldehyde solution at room temperature
for 10 min, washed twice with PBS, permeabilized with 0.5%
Triton-X 100 for 10 min, and washed twice with PBS. The cells
were blocked with 3% BSA in PBS for 30 min at room
temperature. Primary antibody (anti-HAor anti-PDI cloneRL77,
Affinity Bioreagents) diluted 1:100 in blocking buffer was added
and incubated for 1 h at room temperature. Cells were washed
three times in PBS, 5 min each wash. The secondary antibody
Cy5-labeled anti-mouse IgG (Jackson ImmunoResearch Labo-
ratories, West Grove, PA) was diluted 1:200 and incubated for 1
h at room temperature followed by 3 PBS washes.
Confocal microscopy
Cells were examined with a Leica SP2-AOBS confocal
microscope with a 63× oil immersion 1.4 NA objective. GFP/
YFP and Cy5 were excited with lasers at 488 and 633 nm,
respectively. DIC images were collected simultaneously using a
transmitted light detector. Images were processed using Leica
TCS-NT/SP software.
Flow cytometry
Adherent cells were washed with PBS buffer, detached in
PBS supplemented with 2 mM EDTA and 1% FCS, andresuspended in Staining Buffer (0.2% BSA and 0.09% sodium
azide in PBS pH 7.4). Suspension cells were washed with PBS
and resuspended in Staining Buffer. Primary antibody (final
concentration: 10 μg/ml) was added to 100 μl of cells (5 × 106/
ml) for 30 min on ice. Cells were washed twice with 2 ml cold
Wash Buffer (PBS + 2 mM EDTA + 1% FBS). Secondary
antibody (Sigma, FITC–anti-mouse, 1:100) was added and
incubated 30 min on ice followed by two washes with 2 ml cold
Wash Buffer. Cells were resuspended in 0.5 ml Staining Buffer
supplemented with 20 μl 7-AAD viability probe (Pharmingen
cat# 555816). Flow cytometry was performed using a
FACSCalibur (BD Biosciences, San Jose, CA), and data were
analyzed using FlowJo (Tree Star, Ashland, OR) software.
Cell fusion assay
Target and effector cells were trypsinized 24–48 h after
transfection and co-cultivated in triplicate in 24-well plates for
6–16 h. Luciferase activity was assayed using a kit from
Promega (Madison, WI) following the manufacturer's manual.
Briefly, cells were washed once with PBS buffer after co-
cultivation and lysed in 200 μl 1× passive lysis buffer at 4 °C
with shaking for 30 min. The cell lysate was cleared by
centrifugation at 13,000 rpm for 5 min. One hundred microliters
of substrate was added to 20 μl of supernatant, and emitted light
was measured using a VICTOR plate luminometer (Perkin-
Elmer). LacZ was measured in the same way using a
GalactoStar sustrate (Tropix, Bedford, MA). DTNB (5, 5′-
dithiobis(2-nitrobenzoic acid)) (Sigma) was added during cell
co-cultivation, as indicated. Transfection efficiency and DTNB
cytotoxicity were measured by assaying renilla luciferase in the
same tube with firefly luciferase using Promega Dual-
Luciferase Reporter Assay System.
Pseudotyped HIV-1 virus and virus infection
To make VSV-G pseudotyped HIV-1 luciferase vector, 293T
cells were co-transfected with pNL4-3.Luc.R-E− (Connor et al.,
1995; He et al., 1995) with pVSVG (Clontech) at a ratio of 10:1.
MLV LacZ pseudotypes were made in the same way using pCL-
MFG-LacZ. The supernatant was collected 48 h after
transfection and filtered (0.45 μm). HIV-1 virus or VSV-G
pseudotyped virus was added to TZM cells or PDI knockdown
cells. The medium was changed 24 h later, and lacZ or
luciferase activity was assayed 48–60 h after infection. LacZ
and luciferase assays usually gave comparable results in TZM-
bl cells transactivated by Tat; in unactivated TZM-bl cells, the
lacZ activity was lower than luciferase activity.
Thioredoxin reduction of gp120 in vitro
HIV-1 gp120 (Bal strain, from NIH AIDS Research and
Reference Reagent Program, cat# 4961), 2-domain CD4 (from
NIH AIDS Research and Reference Reagent Program, cat#
7356) (Garlick et al., 1990), and thioredoxin (Sigma, cat# T-
8690) were incubated alone or in combinations in 20 μl PBS
without divalent cations at final concentrations of 0.08 μM,
416 W. Ou, J. Silver / Virology 350 (2006) 406–4170.4 μM, and 5 μM, respectively, for 1 h at room temperature.
Biotin was covalently coupled to free thiols by adding 1 μl of
2 mM N-(3-maleimidopropionyl)biocytin (MPB, Fluka, Mil-
waukee, WI) in dimethyl formamide and incubating for 1 h at
room temperature. The reaction was stopped by adding 1 μl
of 4 mM glutathione. Half of each sample was heated for
10 min at 70 °C in 1× LDS sample buffer with reducing
reagent (Invitrogen), electrophoresed in precast 4–12%
gradient bis–tris polyacrylamide gel in MES buffer (Invitro-
gen), transferred to PVDF membrane, blocked with biotin-free
blocking reagent (Pierce cat# 37535) and probed with strep-
tavidin peroxidase.
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